Monte Rosa Therapeutics Inc
Company Profile
Business description
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Contact
321 Harrison Avenue
Suite 900
BostonMA02118
USAT: +1 617 949-2643
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
103
Stocks News & Analysis
stocks
What next for the largest company on the ASX?
stocks
Ask the analyst: Are IDP Education's woes temporary?
stocks
Is it time to buy the Magnificent Seven?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,013.30 | 46.70 | 0.59% |
CAC 40 | 8,028.28 | 90.07 | 1.13% |
DAX 40 | 22,986.82 | 419.68 | 1.86% |
Dow JONES (US) | 41,488.19 | 674.62 | 1.65% |
FTSE 100 | 8,632.33 | 89.77 | 1.05% |
HKSE | 23,959.98 | 497.33 | 2.12% |
NASDAQ | 17,754.09 | 451.07 | 2.61% |
Nikkei 225 | 37,053.10 | 263.07 | 0.72% |
NZX 50 Index | 12,266.25 | 57.20 | 0.47% |
S&P 500 | 5,638.94 | 117.42 | 2.13% |
S&P/ASX 200 | 7,789.70 | 40.60 | 0.52% |
SSE Composite Index | 3,419.56 | 60.83 | 1.81% |